Prescription of antidiabetic compounds and glycemic control in adults with type 2 diabetes: Data of the DPV-Registry from 2005 to 2021

In the present study with data of the DPV registry the usage of different antidiabetic agents in the observation period from 2005 to 2021 has been analyzed. Among 405 790 people with diabetes mellitus (type 2 greater or equal 18 years of age) 2 464 078 patient years could be analyzed. 53,4% were men, the median age was 70,91 years with median diabetes duration slightly above 9 years. The proportion of people over 80 years increased continuously.There was a slightly, but continuously decrease of only with Insulin treated as well as only with lifestyle treated patients. Overall, the prescription of metformin increased through the whole period. While the proportion of the usage of sulfonylureas decreased constantly, the usage of DPP-IV-inhibitors increased almost reciprocal. Since approximately 2015 there is a marked increase of the usage as well of SGLT-2 inhibitors as well as for GLP-1 receptor agonists with a gradually flattening and decreasing proportion of DPP-IV-inhibitors in the same period.While Metformin was used more and more parallel in all investigated age groups there was an increase of the usage of of SGLT-2 inhibitors and GLP-1 receptor agonists primarly in the younger age groups and with time shift even in older age groups.There was no gender difference in the use of GLP-1 receptor agonists, for the Metformin use there was a slight difference with preponderance in the male group, more pronounced in the proportion of SGLT-2 inhibitor use.The glycemic control in terms of median HbA1c is 7,11 % (54,2 mmol/Mol) throughout the whole cohort with an almost unchanged trajectory from 2005 to 2021. There was a clear difference with the lowest HbA1c values in the oldest group and highest in the youngest group.The data were analyzed and discussed on the background of changing guidelines and statement papers.